GeneDX stock drops 45% after revenue miss; investigation into securities violations launched

GeneDX Holdings Corp.'s stock fell over 45% following a first-quarter revenue report below analyst expectations and a lowered 2026 revenue forecast. The company cut its full-year revenue guidance from $540-$555 million to $475-$490 million. Block & Leviton is investigating potential securities law violations related to these developments and is encouraging affected investors to contact them for possible recovery of losses. The firm may pursue legal action if violations are found and also invites whistleblowers with non-public information to assist in the investigation.